

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2022/10/04/2527639/0/en/Arbor-Biotechnologies-to-Participate-in-the-2022-Cell-Gene-Meeting-on-the-Mesa.html
https://www.biospace.com/article/releases/azurity-pharmaceuticals-to-acquire-and-merge-with-arbor-pharmaceuticals/?s=79
https://www.pharmacompass.com/pdf/news/enforcement-report-for-week-of-october-7-2020-1602054141.pdf
https://www.biospace.com/article/releases/arbor-presents-data-from-pivotal-study-of-ar19-an-investigational-adhd-prescription-stimulant-treatment-specifically-designed-to-resist-physical-manipulation-for-nonmedical-misuse-or-abuse/
https://www.prnewswire.com/news-releases/arbor-pharmaceuticals-llc-confirms-availability-of-triptodur-triptorelin-for-patients-with-central-precocious-puberty-301118136.html
https://www.prnewswire.com/news-releases/arbor-pharmaceuticals-llc-confirms-availability-of-triptodur-triptorelin-for-patients-with-central-precocious-puberty-301118136.html#:~:text=ATLANTA%2C%20Aug.%2025%2C%202020,years%20of%20age%20and%20older
https://www.prnewswire.com/news-releases/arbor-pharmaceuticals-announces-fda-filing-acceptance-of-new-drug-application-nda-for-ar19-an-investigational-adhd-prescription-stimulant-treatment-specifically-designed-to-resist-physical-manipulation-for-nonmedical-misuse-or--301058148.html